JP2024539641A5 - - Google Patents

Info

Publication number
JP2024539641A5
JP2024539641A5 JP2024522321A JP2024522321A JP2024539641A5 JP 2024539641 A5 JP2024539641 A5 JP 2024539641A5 JP 2024522321 A JP2024522321 A JP 2024522321A JP 2024522321 A JP2024522321 A JP 2024522321A JP 2024539641 A5 JP2024539641 A5 JP 2024539641A5
Authority
JP
Japan
Prior art keywords
methods
substantially described
novel products
manufacturing methods
manufacturing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539641A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078023 external-priority patent/WO2023064843A1/en
Publication of JP2024539641A publication Critical patent/JP2024539641A/ja
Publication of JP2024539641A5 publication Critical patent/JP2024539641A5/ja
Pending legal-status Critical Current

Links

JP2024522321A 2021-10-15 2022-10-13 癌の治療に使用するための変異ｒｅｔキナーゼの阻害剤 Pending JP2024539641A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163256037P 2021-10-15 2021-10-15
US63/256,037 2021-10-15
US202263358897P 2022-07-07 2022-07-07
US63/358,897 2022-07-07
PCT/US2022/078023 WO2023064843A1 (en) 2021-10-15 2022-10-13 Inhibitors of mutant ret kinases for use in treating cancer

Publications (2)

Publication Number Publication Date
JP2024539641A JP2024539641A (ja) 2024-10-29
JP2024539641A5 true JP2024539641A5 (cg-RX-API-DMAC10.html) 2025-10-22

Family

ID=84238097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522321A Pending JP2024539641A (ja) 2021-10-15 2022-10-13 癌の治療に使用するための変異ｒｅｔキナーゼの阻害剤

Country Status (4)

Country Link
US (1) US20250064809A1 (cg-RX-API-DMAC10.html)
EP (1) EP4415718A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024539641A (cg-RX-API-DMAC10.html)
WO (1) WO2023064843A1 (cg-RX-API-DMAC10.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011000216A (es) * 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
KR102706837B1 (ko) 2016-04-15 2024-09-19 캔써 리서치 테크놀로지 리미티드 Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
GB201705971D0 (en) * 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
EP3740491A1 (en) * 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (zh) * 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物

Similar Documents

Publication Publication Date Title
JP2023134518A5 (cg-RX-API-DMAC10.html)
JP2026048925A5 (cg-RX-API-DMAC10.html)
JP2022538004A5 (cg-RX-API-DMAC10.html)
JP2023113641A5 (cg-RX-API-DMAC10.html)
JP2024156852A5 (cg-RX-API-DMAC10.html)
JP2024133471A5 (cg-RX-API-DMAC10.html)
JP2026012786A5 (cg-RX-API-DMAC10.html)
JP2023113681A5 (cg-RX-API-DMAC10.html)
JP2024037765A5 (cg-RX-API-DMAC10.html)
JP2023154065A5 (cg-RX-API-DMAC10.html)
JP2023164986A5 (cg-RX-API-DMAC10.html)
JP2025023938A5 (cg-RX-API-DMAC10.html)
JP2023153863A5 (cg-RX-API-DMAC10.html)
JP2025106258A5 (cg-RX-API-DMAC10.html)
JP2025118771A5 (cg-RX-API-DMAC10.html)
JP2024156705A5 (cg-RX-API-DMAC10.html)
JP2023134519A5 (cg-RX-API-DMAC10.html)
JP2023139025A5 (cg-RX-API-DMAC10.html)
JP2023103231A5 (cg-RX-API-DMAC10.html)
JP2025038009A5 (cg-RX-API-DMAC10.html)
JP2024088648A5 (cg-RX-API-DMAC10.html)
JP2024156672A5 (cg-RX-API-DMAC10.html)
JP2018100276A5 (cg-RX-API-DMAC10.html)
JP2025163046A5 (cg-RX-API-DMAC10.html)
JP2025143267A5 (cg-RX-API-DMAC10.html)